Business Wire

Nel ASA: Receives Purchase Order for 20MW Alkaline Electrolyser From Ovako

Share

Nel Hydrogen Electrolyser AS, a division of Nel ASA (Nel, OSE:NEL), has received a purchase order for a 20MW alkaline water electrolyser from Ovako, a leading European manufacturer of engineering steel. The electrolyser will be installed at Ovako’s existing plant in Hofors, Sweden. The fossil-free hydrogen will replace the use of fossil propane gas currently used in the heating furnaces.

“We are excited to announce the delivery of electrolyser equipment to Ovako. There is huge potential in reducing CO2-emissions from steel-heating processes through green hydrogen. We look forward to working with Ovako and its partners to further develop fossil-free steel production,” says Jon André Løkke, CEO at Nel.

The purchase order has a contract value of approximately EUR 11 million with equipment delivery in late 2022. The electrolyser will produce oxygen and hydrogen for Ovako’s steel-heating process and is a major step towards zero-carbon emission steel production. The conversion to hydrogen will enable Ovako to reduce its CO2 emissions for steel production in Hofors by 50 percent.

“In June we announced our collaboration with the Volvo Group, Hitachi Energy, H2 Green Steel and Nel Hydrogen with the purpose to invest in fossil-free hydrogen in Hofors. An investment that also got the support from the Swedish Energy Agency. We are very pleased to have reached this important milestone. The electrolyser technology will enable us to eliminate CO2 for heating steel before rolling,” says Rickard Qvarfort, President Business unit Hofors.

Ovako is a leading European manufacturer of engineering steel for customers e.g. in the bearing, transportation and manufacturing industries, and is a subsidiary of Sanyo Special Steel and part of the Nippon Steel Corporation Group. The company has geographical presence in Europe, North America and Asia, and a steel product line that includes niche products and customized solutions. The carbon footprint of Ovako’s steel products is a full 80 percent lower than the global average.

Reference is made to the press release from June 22, 2021: Nel ASA: Joins hydrogen initiative with leading players to enable fossil-free steel rolling/milling.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Jon André Løkke, CEO, +47.907.44.949
Kjell Christian Bjørnsen, CFO, +47.917.02.097
info@nelhydrogen.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Bank of Queensland Goes Live on Temenos Banking Cloud18.8.2022 08:30:00 CEST | Press release

Temenos (SIX: TEMN) today announced that Bank of Queensland (BOQ) has gone live with retail banking services on Temenos Banking Cloud for customers served under the BOQ and Virgin Money brands. Work has commenced on the migration of BOQ’s ME brand to Temenos Banking Cloud. Using Temenos cloud-based platform enables BOQ to offer superior customer propositions with personalized offerings at a fraction of the cost of its legacy systems, building a competitive advantage and a low cost-income ratio. Since go live, BOQ has completed over four million transactions on the new platform. The modernization project with Temenos simplifies BOQ’s technology landscape by consolidating 40 systems to a single platform for retail and business banking. As part of the project, BOQ Group will migrate all of its banking operations across three banking brands – leading regional bank BOQ, and challenger banks Virgin Money and ME Bank. BOQ Group is progressively rolling out the Temenos Banking Cloud across the

Altium, IPC Education Foundation, and Arduino Announce Student Electronics Design Competition18.8.2022 07:00:00 CEST | Press release

Altium LLC, the leading printed circuit board (PCB) design software company, is partnering with the IPC Education Foundation (IPCEF) and Arduino to launch the second annual student electronics design challenge. This competition aims to engage, educate, and enhance PCB design capabilities while developing STEM solutions to environmental challenges. The electronics design challenge is an excellent opportunity for students to showcase their talents and gain real-world experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220817005660/en/ Altium LLC, the IPC Education Foundation, and Arduino are partnering to launch the second annual student electronics design challenge to engage, educate, and enhance students’ proficiencies in PCB design capabilities with a focus on solving some of the world’s most pressing environmental challenges. (Photo: Altium LLC) The Innovation for Environmental Change 2022 International Student Desi

Tavneos ® (avacopan) recommended by England’s NICE for the treatment of AAV (GPA/MPA)18.8.2022 07:00:00 CEST | Press release

Vifor Fresenius Medical Care Renal Pharma (VFMCRP) is pleased to announce that England’s National Institute for Health and Care Excellence (NICE) has recommended Tavneos® in combination with a rituximab or cyclophosphamide regimen for the treatment of adult patients with severe, active granulomatosis polyangiitis (GPA) or microscopic polyangiitis (MPA), two main forms of AAV. The decision follows authorization from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) in May 2022. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220817005538/en/ “ANCA-associated vasculitis is a rare, systemic disease which can be rapidly fatal if not appropriately & promptly treated. The variable nature of the disease and its course along with challenging side-effects of current treatment options can severely affect subsequent quality of life for patients,” said John Mills, Vice-Chair of Vasculitis UK. “We very much welcome NICE’

Pre-registration Opens for Hotly Anticipated Racing Game KartRider: Drift18.8.2022 06:01:00 CEST | Press release

Starting today, Nexon’s upcoming party game, KartRider: Drift, is opening pre-registration to racers in preparation for the game’s launch on PC (Steam and Nexon Launcher), Xbox One, PlayStation 4, and mobile (iOS and Android). Kart racer fans who sign up beforehand can receive a special character Model Student Diz when the game officially launches. Additionally, an upcoming cross-platform play test will be announced soon. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220817005798/en/ Nexon America KartRider: Drift (Graphic: Nexon) KartRider: Drift boasts multiple game modes and features, delivering exciting racing gameplay regardless of what platform you choose to play. 3 Thrilling Game Modes – Racers can test their grit in “Speed Mode,” a fast-paced mode that will test a racer's reaction skills and strategy using boosts. “Item Mode” offers a wide variety of usable items to attack opposing teams or defend their allies. Fina

Exscientia Business Update for Second Quarter and First Half 202217.8.2022 22:01:00 CEST | Press release

Exscientia plc (Nasdaq: EXAI) This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220817005681/en/ Recent developments in the Company’s pipeline, collaborations, and operations, as well as financial results for the second quarter and first half 2022, are summarised below. In addition, Exscientia will host a conference call Thursday, August 18 at 1:30 p.m. BST / 8:30 a.m. ET to provide an overview of the company’s pipeline and corporate strategy. “In the first half of 2022, we delivered on major new and existing collaborations, advanced our pipeline programmes, and marked the 10-year anniversary of Exscientia’s founding. Over the past decade, we’ve pioneered an AI-driven approach to modernising drug discovery and development, and it was fitting that this quarter we also announced topline data from our EXS-21546 programme, one of the first AI-designed molecules to enter clinical trials,” said Andrew Hopkins, D.Phil., Exscientia's f